.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
S3V Vascular Technologies recently reached a major milestone in Indian medical innovation. They announced plans to move their indigenous TAVR system India into preclinical evaluation. This phase will validate the safety and design performance of the balloon-expandable device. Consequently, the company hopes for a commercial launch within the next 18 months.
Transcatheter Aortic Valve Replacement (TAVR) offers a minimally invasive alternative for severe aortic stenosis. Traditionally, patients required open-heart surgery for valve issues. However, clinicians can now replace the valve via a catheter. This method significantly reduces recovery time for high-risk or elderly patients. Furthermore, domestic innovation ensures that the technology meets local clinical needs effectively.
Currently, India performs only 4,000 TAVR procedures annually. Nevertheless, the clinical need exceeds 50,000 cases each year. High costs of imported devices create a significant barrier for many patients. Imported systems usually cost between ₹13 lakh and ₹23 lakh. Therefore, S3V aims to democratize care by providing a high-quality, local alternative. This shift could transform cardiac care delivery across the country.
Q1: What is the main benefit of the S3V TAVR system?
A1: It aims to provide a high-quality, affordable local alternative to expensive imported heart valves, increasing accessibility for Indian patients.
Q2: When will the new TAVR system be available?
A2: S3V plans to launch the device commercially within 12 to 18 months, pending successful trials and regulatory approvals.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
S3V Vascular Technologies moves its indigenous TAVR system into preclinical trials to lower costs and improve access to cardiac care for Indian patients....
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
